A Disintegrin and Metalloproteinase 8 as a Potential Blood Biomarker for Early Diagnosis of Gastric Cancer

Hye Won Chung, Jin Ju Kim, Jae Il Choi, Hae Rim Lee, and Jong-Baeck Lim
Department of Laboratory Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.

**Purpose:** We aimed to evaluate the clinical significance of a disintegrin and metalloproteinase 8 (ADAM 8) as a potential blood biomarker for gastric cancer (GC).

**Materials and Methods:** Blood ADAM 8 was measured by ELISA. Cytokines/chemokines [interleukin-23 (IL-23), stromal cell-derived factor 1α/CXC chemokine ligand 12 (SDF-1α/CXCL12), interleukin-8 (IL-8), and soluble CD40 ligand (sCD40L)] were measured by chemiluminescent immunoassay. They were compared among five groups; normal/gastritis, high-risk, early GC (EGC), advanced GC (AGC) without distant metastasis, and AGC with distant metastasis by one-way analysis of variance in both training (n=80) and validation dataset (n=241). Clinicopathological features of GC and GC-associated cytokines were evaluated for their correlations with blood ADAM 8. To evaluate the diagnostic accuracy to predict GC, receiver operating characteristic (ROC) curve and logistic regression were used.

**Results:** Blood ADAM 8 significantly increased along GC carcinogenesis in both training (ANOVA, *p*<0.001) and validation dataset (*p*<0.001). It was significantly higher in EGC compared to high-risk (post-hoc Bonferroni, *p*=0.041) and normal (*p*<0.001). It was also higher in AGC compared with high-risk (*p*<0.001) and normal (*p*<0.001) groups. However, no significant difference was found between cancer groups. Blood ADAM 8 was correlated with N-stage (Spearman’s correlation, γs=0.320, *p*=0.011), but not with T-stage or M-stage. Pearson’s correlations showed blood ADAM 8 was closely correlated with pre-inflammatory cytokines, IL-23 (*p*=0.036) and SDF-1α/CXCL12 (*p*=0.037); however, it was not correlated with pro-angiogenic cytokine IL-8 (*p*=0.313), and sCD40L (*p*=0.702). ROC curve and logistic regression demonstrated that blood ADAM 8 showed higher diagnostic accuracy (sensitivity, 73.7%; specificity, 86.2%) than CEA (sensitivity, 23.1%; specificity, 91.4%). Combination of ADAM 8 and CEA further increased the diagnostic accuracy to predict GC (sensitivity, 81.8%; specificity, 84.0%).

**Conclusion:** Blood ADAM 8 is a promising biomarker for early detection of GC.

**Key Words:** A disintegrin and metalloproteinase (ADAM 8), blood biomarker, diagnostic, gastric cancer, early detection

---

**INTRODUCTION**

Gastric cancer (GC) is the fourth most common cancer and the second leading cause of cancer-related deaths worldwide. 1 Although the survival rates of GC still remain poor, 2 the overall 5-year relative survival rate has increased, especially in Northeast Asia. 3 Such high survival rates may be due to the effectiveness of mass screening programs for early detection of GC using endoscopic examination and GC-specific biomarkers in this area. 4 Therefore, early diagnosis of localized GC using screening programs is clinically important. Endoscopic examination is an ideal, highly reliable technique for early detection of GC, but its usefulness for GC screening is somewhat limited compared to serological biomarkers due to its high cost and the risks associated with the invasive procedure. Serological tumor biomarkers should have significant advantages as they are easily...
MATERIALS AND METHODS

Study groups
Study groups were classified into five groups according to “gastritis-dysplasia-carcinoma” sequence of gastric carcinogenesis, and analyzed the correlations between blood ADAM 8 levels along GC carcinogenesis sequence and GC clinicopathological parameters, or their potential as a desirable blood biomarker for predicting GC development or progression.

In this study, we evaluated the blood ADAM 8 levels along “gastritis-dysplasia-carcinoma” sequence of gastric carcinogenesis, and validated blood ADAM 8 as a potential biomarker candidate for GC and compared it to serum CEA, a pre-existing biomarker for gastrointestinal tumors, using human blood samples.

For the initial training dataset, a total of 80 subjects were enrolled. The following numbers of subjects were enrolled in each group: 20 in normal control group, 10 in dysplasia group, 20 in EGC group, 20 in AGC without metastasis group, and 10 in AGC with metastasis group.

For independent validation dataset, a total of 241 subjects were enrolled. The following number of subjects were enrolled in each group: 70 in normal control group, 24 in dysplasia group, 70 in EGC group, 50 in AGC without metastasis group, and 27 in AGC with metastasis group.

All subjects underwent upper gastrointestinal endoscopy (Types XQ-260, Olympus, Tokyo, Japan) in gastroenterology outpatient clinics or health check-up center of Gangnam Severance Hospital, Yonsei University College of Medicine, due to gastric symptom or routine check-up. Diagnosis was made based on histological findings via biopsy or surgical specimens. All patients were diagnosed for the first time during the enrollment period, and their blood samples were collected before they received any treatments. All patients in the cancer groups received imagining studies such as chest X-ray, abdominal-pelvic helical computed tomography, and whole-body positron emission tomography (PET) scan for TNM stage. TNM stage of GC was evaluated according to the 7th International Union Against Cancer-TNM stage for GC via radiological studies or surgical findings. Histopathologic differentiation was diagnosed using Lauren classification. Subjects who suffered from chronic diseases such as liver cirrhosis, chronic renal disease, and diabetes mellitus were excluded. Subjects with other cancers and gastric neoplasm such as gastrointestinal stromal tumor, mucosa-associated lymphoid tissue lymphoma, and neuroendocrine tumors were also excluded. Additionally, patients with a history of any previous treatment for GC or its premalignant lesions were also excluded.

Ethics statement
The current study was approved by the institutional review board of Yonsei University Health System (3-2019-0044), and all procedures were conducted according to the principles expressed in the Declaration of Helsinki. We enrolled subjects based on clinicopathological information such as age, gender, and disease contents using chart review blind to any personal information. Therefore, this study presented minimum risk to subjects and did not violate the right and welfare of subjects. We did our best to protect subjects’ privacy and anonymity.

Measurement of blood levels of ADAM 8, CEA, IL-23; SDF-1α/CXCL12; IL-8 and sCD40L
Blood ADAM 8 levels were measured using a commercially available ELISA kit (SEA620Hu, CLOUD-CLONE, Katy, TX, USA). Briefly, all reagents, blood samples, and standards were prepared. In addition, 100 μL standards or blood samples were added to each well in the pre-coated 96-well plate and reacted at 37°C for 1 hour. After aspiration, the cells were washed three
times, and then 100 μL of the prepared Reagent B was added, followed by reaction at 37°C for 30 minutes. After five times of aspiration and washing, 90 μL of the substrate solution was added and reacted at 37°C for 10–20 minutes. Finally, blood ADAM 8 levels were measured at 450 nm using VERSA max microplate reader (Molecular Devices Co., Sunnyvale, CA, USA). Blood CEA levels were measured using Beckman Access CEA assay (Beckman Coulter Inc., Chaska, CA, USA). Blood levels of interleukin-23 (IL-23), stromal cell-derived factor 1α (SDF-1α), interleukin-8 (IL-8), and soluble CD40 ligand (sCD40L) were measured by a commercially available MILLIPLEX MAP Human Cytokine/Chemokine Kit (Millipore, Billerica, MA, USA) using a chemiluminescent immunoassay according to the manufacturer’s instructions. Briefly, filter plate was pre-wetted with 200 microliters (μL) assay buffer for 10 min at room temperature (RT), followed by vacuum removal of assay buffer. Twenty-five μL of standard or control was added to the appropriate well, and 25 μL assay buffer was added to the sample wells, but not the background well. Next, 25 μL of the appropriate matrix solution was added to the background, standard, and control wells, followed by addition of 25 μL sample to appropriate wells. After mixing, 25 μL beads were added, and the plate was incubated overnight at 4°C with shaking. After incubation, the fluid was removed and the plate was washed twice. Detection antibodies (25 μL) were added, and the plate was incubated for 1 h at RT with shaking. Streptavidin-phycocerythrin (25 μL) was added to each well containing 25 μL detection antibodies and was incubated for 1 h at RT with shaking. Fluid was then removed, the plate was washed, and 150 μL sheath fluid was added. After re-suspension for 5 min, the median fluorescent intensity was read on Luminex 100™ IS (Luminex, Austin, TX, USA) and analyzed using logistic curve-fitting method to determine chemokine concentrations.

Statistical analysis

All assays were blinded and performed on the same day. Each value is expressed as mean with 25%–75% standard deviation. Mean of each group was compared by ANOVA test with multiple comparisons using post-hoc Bonferroni method. An independent sample t-test was used to compare the means between cancer and non-cancer conditions. To evaluate the correlations between serum levels of tested values and clinicopathological parameters, Pearson’s correlation (coefficient, \( r_p \)) and Spearman’s correlation (coefficient, \( \gamma_s \)) were performed, respectively. Primary GC size was classified into three groups of <3 cm, 3–5 cm, and >5 cm, in order to analyze the relationship between primary GC size and blood ADAM 8 levels. Receiver operating characteristic (ROC) curves were generated, and area under curve (AUC) was calculated to compare the diagnostic accuracy of each value to predict the presence of GC. Logistic regression analysis was performed to obtain the best sensitivity/specificity to predict the presence of GC as a single-marker or as a multiple-markers panel. Each marker was included as a linear term.

RESULTS

Blood levels of ADAM 8 compared to CEA in five groups (initial training dataset)

A total of 80 subjects were enrolled in initial training dataset. Blood ADAM 8 and CEA were measured according to GC carcinogenesis (five disease groups), and then compared among groups. Table 1 shows that the mean of blood ADAM 8 was significantly different among groups (ANOVA, \( p<0.001 \), Table 1, upper panel). ADAM 8 levels were remarkably increased from the early stage of GC. Table 1 shows that mean levels of ADAM 8 were remarkably higher in EGC group compared to dysplasia group (high-risk, post-hoc Bonferroni, \( p<0.01 \)) and normal control group (control, post-hoc Bonferroni, \( p<0.01 \)). However, blood ADAM 8 levels were not significantly different among cancer groups despite a tendency that these levels were maximized at locally advanced AGC without metastasis (post-hoc Bonferroni between EGC and AGC, \( p=0.086 \)) and then slightly decreased after distant metastasis without statistical significance.

When the mean blood ADAM 8 levels were compared between cancer and non-cancer groups, levels in cancer groups (65.4±44.0 ng/mL) were significantly higher than those in non-cancer groups (6.2±10.1 ng/mL, t-test, \( p<0.001 \), Table 1, lower panel).

Blood mean of CEA levels were not significantly different among groups, except in metastatic cases of AGC groups (Table 1, upper panel). This value was significantly elevated only in AGC with metastasis groups (ANOVA, \( p=0.013 \)). When blood mean of CEA levels was compared between cancer and non-cancer groups, no significant difference was found between cancer and non-cancer (\( p=0.235 \), t-test, Table 1, lower panel).

Blood levels of ADAM 8 compared to CEA according to GC carcinogenic sequences in the following independent validation dataset

To test the reproducibility of results from the initial training dataset, we used an independent validation dataset. A total of 241 subjects were enrolled in validation dataset. Similar to the results of training dataset, mean of blood ADAM 8 were increased along carcinogenic sequences; mean of blood ADAM 8 were 6.4±8.7 ng/mL in normal/gastritis group, 23.7±16.0 ng/mL in dysplasia group, 54.5±42.7 ng/mL in EGC group, 82.8±52.6 ng/mL in AGC without distant metastasis, and 53.6±26.3 ng/mL in AGC with distant metastasis, respectively. Interestingly, blood mean levels of ADAM 8 were remarkably increased from the early stage of GC.

When the mean blood ADAM 8 levels were compared between cancer and non-cancer groups, levels in cancer groups (65.4±44.0 ng/mL) were significantly higher than those in non-cancer groups (6.2±10.1 ng/mL, t-test, \( p<0.001 \)). When blood mean of CEA levels was compared between cancer and non-cancer groups, no significant difference was found between cancer and non-cancer (\( p=0.235 \), t-test, Table 1, lower panel).
Table 1. Serum Levels of ADAM 8 and CEA according to GC Carcinogenic Sequence (Upper Panel) and between Non-Cancer and Cancer Groups (Lower Panel) in Initial Training Dataset

| Groups (N) | Normal/Gastritis (20) | Dysplasia (10) | EGC (20) | AGC (20) | Metastasis (10) | p value* | Non-cancer groups (30) | Cancer groups (50) | p value† |
|------------|----------------------|----------------|---------|---------|----------------|---------|------------------------|------------------|---------|
| Serum ADAM 8 (ng/mL) | 1.7±2.6              | 15.2±13.3      | 53.9±36.9 | 82.8±52.6 | 53.6±26.3      | <0.001  | 6.2±10.1               | 65.4±44.0        | <0.001  |
| Serum CEA (ng/mL)   | 1.9±1.1              | 3.7±1.9        | 2.0±1.2  | 3.6±6.7  | 9.8±14.1       | 0.013   | 2.5±1.6                | 4.2±7.9          | 0.235   |

ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembryonic antigen; GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer. Values are expressed as mean±standard deviation.

*One-way analysis of variance test with multiple comparisons using post-hoc Bonferroni method was used to compare differences in means among disease groups; †An independent sample t-test was used to compare differences in means between non-cancer and cancer groups. p<0.05 (two-tailed) was considered statistically significant.

Table 2. Serum Levels of ADAM 8 and CEA according to GC Carcinogenic Sequence (Upper Panel) and between Non-Cancer and Cancer Groups (Lower Panel) in Validation Dataset

| Groups (N) | Normal/Gastritis (70) | Dysplasia (24) | EGC (70) | AGC (50) | Metastasis (27) | p value* | Non-cancer groups (94) | Cancer groups (148) | p value† |
|------------|----------------------|----------------|---------|---------|----------------|---------|------------------------|------------------|---------|
| Serum ADAM 8 (ng/mL) | 6.4±8.7              | 23.7±16.0      | 54.5±42.7 | 67.9±55.1 | 55.0±29.7      | <0.001  | 10.8±13.3              | 59.1±45.4        | <0.001  |
| Serum CEA (ng/mL)   | 1.9±1.0              | 3.5±4.3        | 2.1±1.4  | 2.5±2.8  | 6.7±4.3        | <0.001  | 2.3±2.4                | 3.0±3.1          | 0.053   |

ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembryonic antigen; GC, gastric cancer; EGC, early gastric cancer; AGC, advanced gastric cancer. Values are expressed as mean±standard deviation.

*One-way analysis of variance test with multiple comparisons using post-hoc Bonferroni method was used to compare differences in means among disease groups; †An independent sample t-test was used to compare differences in means between non-cancer and cancer groups. p<0.05 (two-tailed) was considered statistically significant.

Table 3. Relationships between Serum ADAM 8 and Clinicopathological Characteristics of GC in Validation Dataset

| Clinicopathological characteristics | Serum ADAM 8 (γ, p value) |
|------------------------------------|---------------------------|
| Age (yr)*                           | -0.064 (0.319)            |
| Gender (male:female)                | -0.096 (0.143)            |
| Histology (well:mod:poorly:signet-ring)† | 0.139 (0.193)            |
| Tumor location (lower:middle:upper) | 0.058 (0.397)            |
| Tumor size (<3 cm, 3–5 cm and >5 cm)‡ | 0.121 (0.249)            |
| T-stage (T1a:T1b:T2:T3:T4)§         | 0.197 (0.085)            |
| N-stage (N0:N1:N2:N3)‡             | 0.320 (0.011)            |
| Distant metastasis (M0:M1)§         | 0.140 (0.193)            |

ADAM 8, a disintegrin and metalloproteinase domain 8; GC, gastric cancer. *γ* means ‘Spearman’s correlation coefficient. p<0.05 (two-tailed) was considered statistically significant.

†This was a continuous variable. Therefore, correlation was evaluated by Pearson’s correlation (γ). †Well:mod:poorly:signet-ring means ‘well-differentiated carcinoma:moderate-differentiated carcinoma:poorly-differentiated carcinoma:signet-ring cell carcinoma’. ‡Tumor size was classified into three groups: <3 cm, 3–5 cm, and >5 cm. §TNM stage was evaluated according to the 7th International Union Against Cancer-TNM stage guidelines.

Dysgastic relationships were observed (ANOVA, p<0.001, Table 2, upper panel). This value was also significantly increased from the early stage of GC, and it was not significantly different among cancer groups despite a tendency for it to be maximized at locally advanced AGC without metastasis (Table 2, upper panel).

When mean of blood ADAM 8 levels were compared between cancer and non-cancer groups, those of cancer groups (59.1±45.4 ng/mL) were significantly higher than those of non-cancer groups (10.8±13.3 ng/mL, t-test, p<0.001, Table 2, lower panel), similar to the training dataset.

Similar to the results of training dataset, blood mean of CEA levels was significantly elevated only in cases of AGC with metastatic groups compared to other groups, with no significant difference found between cancer and non-cancer groups in validation dataset (Table 2, lower panel).

Relationships between blood levels of ADAM 8 and clinicopathological characteristics of GC in validation dataset

Table 3 showed that blood ADAM 8 levels were not affected by age (Pearson’s correlation; γ=−0.064, p=0.319) and gender (Spearman’s correlation; γ=−0.095, p=0.143). Histopathologically, serum ADAM 8 levels were not significantly correlated with the histological differentiation of GC (γ=0.139, p=0.193), primary GC location (γ=0.058, p=0.397), and primary GC size (γ=0.121, p=0.249). This value was also not correlated with depth of invasion (T-stage, γ=0.197, p=0.085) and distant metastasis (M-stage, γ=0.140, p=0.193) while it was closely correlated with N-stage (γ=0.320, p=0.011).

Diagnostic performance of blood ADAM 8, CEA, and their combination for prediction of GC presence in validation dataset

In validation dataset, ROC curve and calculated AUC of each value suggested that blood ADAM 8 has remarkable diagnostic potential for prediction of GC presence, superior to blood CEA (Fig. 1); AUC was 0.90 (95% CI, 0.86–0.93) in blood ADAM 8 and 0.56 (95% CI, 0.49–0.63) in blood CEA, respectively. Sensitivity and specificity of blood ADAM 8 to predict the presence of GC were 73.7% and 86.2% (cut-off value, 30 ng/mL) as a single-marker by logistic regression analysis (Table 4), which were...
superior to those of blood CEA (23.1% and 91.4%; cut-off value, 4 ng/mL), respectively.

Since the elevated pattern of blood ADAM 8 and CEA were significantly different from each other according to GC stage, combination of these serum markers as a multiple-markers panel was expected to be synergistic. As a multiple-markers panel, combination of serum ADAM 8 (cut-off value, 25 ng/mL) and CEA (cut-off value, 5 ng/mL) exhibited increased diagnostic accuracy compared to a single marker, remarkably (sensitivity, 81.8%; specificity, 84.0%; Table 4).

**Correlations between blood levels of ADAM 8 and cancer-associated cytokines in validation dataset**

To investigate the role of blood ADAM 8 in carcinogenesis and progression of GC, the correlations between blood ADAM 8 levels and several GC-associated pre-inflammatory or pro-angiogenic cytokines levels were evaluated using validation dataset. Table 5 shows that blood ADAM 8 levels were closely correlated with blood IL-23 (γ = 0.235, p = 0.036) and blood SDF-1α/CXC chemokine ligand 12 (CXCL12) (γ = −0.233, p = 0.037), while blood ADAM 8 levels were not closely correlated with blood IL-8 (γ = 0.113, p = 0.313) and blood sCD40L (γ = 0.043, p = 0.702). That is, blood ADAM 8 was closely correlated pre-inflammatory cytokines (IL-23, SDF-1α/CXCL12), while it was not correlated with pro-angiogenic cytokines (IL-8, sCD40L).

**DISCUSSION**

ADAM 8 is a transmembrane protein that belongs to the ADAM family of proteins that mediate cell adhesion and cell migration through the cleavage of membrane-bound cytokines, growth factors, and receptors. A previous report has suggested that ADAM 8 ectodomain is cleaved by ADAM 8 itself. ADAM 8 was known to play potential roles in inflammatory and allergic processes, and further studies have shown that its overexpression is associated with progression and poor survival in various solid tumors. A previous study reported that ADAM 8 in tumor tissue was an independent indicator of lymph node metastasis in human GC; however, its precise effects on GC progression and prognosis remain unclear. In this study, we investigated the clinical usefulness of blood ADAM 8 as a blood biomarker for early detection of GC. We evaluated the clinical implications of blood ADAM 8 as a biomarker for early diagnosis of GC as a single-marker or a part of combination panels, compared to blood CEA, a pre-existing gastrointestinal tumor marker, according to the guideline of Standards for Reporting of Diagnostic Accuracy statement. We found that blood levels of ADAM 8 were significantly different among groups (ANOVA, all p<0.001), and were increased significantly along the GC carcinogenesis in both initial training and following independent validation datasets (Tables 1 and 2, upper panel). These levels were significantly different between cancer and non-cancer groups (t-test, all of p<0.001; Tables 1 and 2, lower panel). Interestingly, this value was elevated from the EGC, different from many pre-existing serum biomarkers such as CEA. This means that the use of blood ADAM 8 may be very meaningful in predicting the presence of GC in replacement of endoscopy as a screening tool. However, blood ADAM 8 levels were not significantly different among cancer groups, although

**Table 4. Comparison of Sensitivity and Specificity of Serum ADAM 8, CEA and Their Combination as Single Markers and/or as a Multiple-Markers Panel for Prediction of GC Determined by Logistic Regression Analysis in Validation Dataset**

| Marker panel* | Cut-off values (ng/mL) | Sensitivity (%) | Specificity (%) |
|---------------|------------------------|----------------|-----------------|
| ADAM 8        | 30                     | 73.7           | 86.2            |
| CEA           | 5                      | 23.1           | 91.4            |
| ADAM 8+CEA    | 25, 5                  | 81.8           | 84.0            |

ADAM 8, a disintegrin and metalloproteinase domain 8; CEA, carcinoembryonic antigen; GC, gastric cancer.

*Each marker was included as a linear term and evaluated as part of a panel of one to two markers in combination.

**Table 5. Pearson’s Correlations among Serum Levels of IL-23, SDF-1α, IL-8, sCD40L, and ADAM 8 in Validation Dataset**

| markers | IL-23 | SDF-1α | IL-8 | sCD40L |
|---------|-------|--------|------|--------|
| ADAM 8  | 0.235 | 0.113  | 0.043| 0.036  |

IL-23, interleukin-23; SDF-1α, stromal cell-derived factor 1α; IL-8, interleukin-8; sCD40L, soluble CD40 ligand.

Values are presented as γ (p-value). γ* means ‘Pearson’s correlation coefficient, p<0.05 (two-tailed) was considered statistically significant.

*Statistically significant values.
there was a tendency that these levels were maximized at locally advanced AGC without metastasis (post-hoc Bonferroni between EGC and AGC, p=0.086), and then slightly deceased after distant metastasis. According to Spearman's correlation analysis (Table 3), no association was found between serum ADAM 8 and either tumor size, depth of invasion (T-stage), and distant metastasis of GC. However, significantly close association was found between serum ADAM 8 and lymph node involvement (N-stage) (Table 3). A previous study reported that ADAM 8 protein expression in GC tissues was significantly correlated with invasion depth (T-stage), lymph node involvement (N-stage), and vessel invasion. The cause of difference between our results and those of previous studies may have originated from the difference in sample types (tissue vs. blood) or relatively small sample size of our study, especially in distant metastatic cases. Therefore, a large-scale study should be performed in the future to confirm these results.

Blood ADAM 8 showed higher diagnostic sensitivity than blood CEA (Fig. 1 and Table 4). Blood ADAM 8 alone showed 73.7% sensitivity and 86.2% specificity for diagnosis of GC. When blood ADAM 8 and blood CEA were combined, this panel showed higher sensitivity for diagnosis of GC (sensitivity; 81.8%, specificity; 84.0%). We also evaluated the diagnostic performance of ADAM 8 for GC using ROC curve and calculated AUC in validation dataset (Fig. 1), and found that AUC (0.90, 95% CI, 0.86–0.93) was remarkable for diagnostic performance of GC. Additionally, blood levels of ADAM 8 demonstrated remarkable sensitivity and performance to predict the presence of GC, compared to blood CEA. To our knowledge, this is the first report to measure the serum levels of ADAM 8 along GC carcinogenic sequences, and the first to evaluate the clinical significance of high-levels of serum ADAM 8 in GC. Additionally, this study is the first to report that combined blood ADAM 8 and CEA are promising biomarkers for GC as part of multiple-marker panels.

ACKNOWLEDGEMENTS

This study was supported by a faculty research grant of Yonsei University College of Medicine for 2014-0093, and a grant from the National Research Foundation of Korea (NRF) funded by the Korea government (MSIT) (2017R1A2B2011728).

AUTHOR CONTRIBUTIONS

Data curation: Hye Won Chung, Jin Ju Kim, and Jong-Baeck Lim. Formal analysis: Hye Won Chung, Jin Ju Kim, Jae Il Choi, and Hae Rim Lee. Funding acquisition: Jong-Baeck Lim. Investigation: Jong-Baeck Lim. Methodology: Jae Il Choi and Hae Rim Lee. Project administration: Hye Won Chung, Jin Ju Kim, Jae Il Choi, and Jong-Baeck Lim. Resources: Jong-Baeck Lim. Software: Hye Won Chung and Jae Il Choi. Supervision: Jong-Baeck Lim. Validation: Hye Won Chung and Jong-Baeck Lim. Visualization: Hye Won Chung and Jong-Baeck Lim. Writing—original draft: Hye Won Chung and Jong-Baeck Lim. Writing—review & editing: Hye Won Chung and Jong-Baeck Lim.

ORCID iDs

Hye Won Chung https://orcid.org/0000-0002-1543-2389
Jin Ju Kim https://orcid.org/0000-0001-9166-1848
Jae Il Choi https://orcid.org/0000-0002-6292-241X
Hae Rim Lee https://orcid.org/0000-0001-7833-4914
Jong-Baeck Lim https://orcid.org/0000-0003-0419-0422

REFERENCES

1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-907.
2. Cunningham SC, Kamangar F, Kim MP, Hammond S, Haque R, Maitra A, et al. Survival after gastric adenocarcinoma resection: eight-year experience at a single institution. J Gastrointest Surg 2005;9:718-25.
3. Isobe Y, Nashimoto A, Akazawa K, Oda I, Hayashi K, Miyashiro I, et al. Gastric cancer treatment in Japan: 2006 annual report of the
1. JGCA nationwide registry. Gastric Cancer 2011;14:301-16.
2. Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-13.
3. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33.
4. Karimi P, Islami F, Anandasabapathy S, Freedman N, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-13.
5. Shimada H, Noie T, Ohashi M, Oba K, Takahashi Y. Clinical significance of serum tumor markers for gastric cancer: a systematic review of literature by the Task Force of the Japanese Gastric Cancer Association. Gastric Cancer 2014;17:26-33.
6. Pectasides D, Mylonakis A, Kostopoulou M, Papadopoulou M, Triantafillidis D, Varthaliitis J, et al. CEA, CA 19-9, and CA-50 in monitoring gastric carcinoma. Am J Clin Oncol 1997;20:348-53.
7. Fan B, Xiong B. Investigation of serum tumor markers in the diagnosis of gastric cancer. Hepatogastroenterology 2011;58:239-45.
8. Duffy MJ, McKiernan E, O’Donovan N, McGowan PM. Role of ADAMs in cancer formation and progression. Clin Cancer Res 2009; 15:1140-4.
9. Aydin D, Bilici A, Yavuzer D, Kefeli U, Tan A, Ercelep O, et al. Prognostic significance of ADAM17 expression in patients with gastric cancer who underwent curative gastrectomy. Clin Transl Oncol 2015;17:604-11.
10. Chen J, Chen X, Wang F, Gao H, Hu W. Dihydroartemisinin suppresses glioma proliferation and invasion via inhibition of the ADAM17 pathway. Neuron Sci 2015;36:435-40.
11. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:621-8.
12. Mullolo M, McGowan PM, Crown J, Duffy MJ. The ADAMs family of proteases as targets for the treatment of Cancer. Cancer Biol Ther 2016;17:870-80.
13. Huang J, Bai Y, Hsu L, Xiao J, Fan X, Yang Z, et al. Upregulation of a disintegrin and metalloprotease 8 is associated with progression and prognosis of patients with gastric cancer. Transl Res 2015;166:602-13.
14. Tong W, Ye F, He L, Cui L, Cui M, Hu Y, et al. Serum biomarker panels for diagnosis of gastric cancer. Onco Targets Ther 2016;9:2455-63.